IDENTIFICATION, ASSESSMENT AND THERAPY OF ESSENTIAL THROMBOCYTHEMIA WITH RESISTANCE TO JAK2 INHIBITORS

摘要

The inventors herein disclose mutations that naturally occur in the JAK2 gene sequence of human patients suffering from essential thrombocythemia and that confer resistance to commonly used JAK2 inhibitors and/or Hsp90 inhibitors. The present invention therefore relates to methods, compositions and kits aiming to detect the presence of these mutations so as to predict and try to overcome the patient resistance to treatment involving JAK2 inhibitors and/or Hsp90 inhibitors. Moreover, the invention describes a model to test new drugs and JAK2 inhibitors.